학술논문
Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a post-hoc analysis
Document Type
article
Author
Emanuela Palmerini; Roberta Sanfilippo; Giovanni Grignani; Angela Buonadonna; Antonella Romanini; Giuseppe Badalamenti; Virginia Ferraresi; Bruno Vincenzi; Alessandro Comandone; Antonio Pizzolorusso; Antonella Brunello; Fabio Gelsomino; Tommaso De Pas; Toni Ibrahim; Lorena Gurrieri; Federica Grosso; Francesca Zanelli; Maria Abbondanza Pantaleo; Laura Milesi; Libero Ciuffreda; Vittorio Ferrari; Emanuela Marchesi; Irene Quattrini; Alberto Righi; Elisabetta Setola; Elisa Carretta; Paolo G. Casali; Piero Picci; Stefano Ferrari
Source
Frontiers in Oncology, Vol 12 (2022)
Subject
Language
English
ISSN
2234-943X
Abstract
BackgroundAmong sarcomas, which are rare cancers with an incidence of 24 months. Nine patients had at least one grade 3/4 adverse event, mostly being bone marrow toxicity (n=6).ConclusionsTrabectedin has some anti-tumor activity in some ultra-rare and other rare sarcomas, particularly translocation-related sarcomas, with the well-known manageable safety profile.